Hemophilia

Detailed Overview

Hemophilia primarily affects males, though females can be symptomatic carriers. The clinical hallmark is deep tissue bleeding, specifically into joints (hemarthrosis) and muscles. Without prophylactic treatment, recurrent joint bleeding causes a destructive inflammatory arthropathy. The clinical significance of hemophilia has evolved dramatically; previously a fatal disease in early adulthood, prophylactic factor replacement and novel non-factor therapies (like emicizumab) now allow patients to lead near-normal lifespans, shifting the clinical focus from acute hemorrhage control to preventing long-term joint damage and managing treatment complications, such as the development of neutralizing antibodies (inhibitors).

Epidemiology & Demographics

Hemophilia A is the most common severe inherited bleeding disorder, occurring in 1 in 5,000 live male births. Hemophilia B occurs in 1 in 30,000 live male births. Affects all racial and ethnic groups equally.

Etiological Mechanism

Caused by mutations in the F8 gene (Hemophilia A) or F9 gene (Hemophilia B) located on the X chromosome (Xq28 and Xq27.1, respectively). An intron 22 inversion in the F8 gene accounts for nearly 50% of severe Hemophilia A cases. Approximately 30% of cases represent de novo (spontaneous) mutations without a family history.

Primary Causes

Inherited X-linked recessive mutation. Spontaneous acquired hemophilia is a distinct, rare autoimmune condition caused by autoantibodies against Factor VIII.

• Family History: Known carrier mother or affected male relatives in the maternal lineage.
• Male Sex: Males (XY) are phenotypically affected, whereas females (XX) are typically asymptomatic carriers, though extreme lyonization (skewed X-inactivation) can cause symptoms in females.

Hemostasis involves primary hemostasis (platelet plug formation) and secondary hemostasis (coagulation cascade leading to a fibrin mesh). Hemophiliacs have normal primary hemostasis (normal platelets/vWF), so they may not bleed excessively from minor superficial cuts. However, FVIII and FIX form the 'tenase' complex in the intrinsic pathway, which is required to amplify thrombin generation. The deficiency prevents adequate fibrin formation. When capillaries in highly vascular synovial joints are subjected to normal daily microtrauma, the fragile clots fail. Blood enters the joint space (hemarthrosis). Iron from degraded red blood cells is taken up by synovial macrophages, triggering severe synovial inflammation, hyperplasia, and the release of proteases that aggressively destroy articular cartilage and bone.

Characteristic Clinical Presentation

• Joint Pain and Swelling: Acute hemarthrosis typically affects hinge joints (knees, elbows, ankles), presenting with sudden pain, warmth, swelling, and decreased range of motion.
• Muscle Bleeds: Deep intramuscular hematomas, notably in the iliopsoas, which can present as severe groin/back pain and inability to extend the hip.
• Prolonged Bleeding post-surgery: Delayed, massive bleeding following circumcision, dental extractions, or minor trauma.

Physical Examination Signs

• Target Joints: Joints that have had ≥3 spontaneous bleeds in 6 months, appearing chronically swollen and deformed.
• Extensive ecchymoses (large bruises) from trivial blunt trauma.

• Hemophilic Arthropathy: Chronic, disabling osteoarthritis secondary to repeated hemarthrosis.
• Inhibitor Development: Development of IgG neutralizing alloantibodies against infused exogenous FVIII or FIX, rendering standard replacement therapy ineffective (occurs in ~30% of severe Hem A).

Diagnostic Criteria & Guidelines

Prolonged Activated Partial Thromboplastin Time (aPTT) with a normal Prothrombin Time (PT) and normal Platelet count. Mixing study corrects the aPTT (unless inhibitors are present). Definitive diagnosis requires specific factor assays showing reduced FVIII or FIX activity levels.

Differential Diagnosis

• Von Willebrand Disease (usually mucosal bleeding, autosomal inherited)
• Vitamin K Deficiency (prolongs PT, not just aPTT)
• Factor XI Deficiency (Hemophilia C)

Laboratory Tests & Biomarkers

• aPTT: Significantly prolonged (e.g., > 60 seconds).
• Factor VIII or IX Activity: Decreased. Example: < 1 IU/dL (or <1%) indicates severe disease.
• Bethesda Assay: Positive if neutralizing 'inhibitor' antibodies are present (measured in Bethesda Units).

Imaging Modalities & Findings

• Joint Ultrasound or MRI:

• Severe
  Spontaneous bleeds into joints or muscles without any identifiable trauma. Usually diagnosed in infancy.
• Moderate
  Occasional spontaneous bleeds, but mostly prolonged bleeding after minor trauma or surgery.
• Mild
  Bleeding only after significant trauma or surgery. Rarely have spontaneous joint bleeds.

Second-Line & Adjunctive Therapy

For mild Hemophilia A: Desmopressin (DDAVP) 0.3 mcg/kg IV or intranasal can transiently release endogenous FVIII and vWF from endothelial cells for minor bleeds. For patients with high-titer inhibitors (>5 BU): Bypassing agents are required, such as Recombinant Factor VIIa (NovoSeven) 90 mcg/kg IV.

Surgical & Procedural Management

Synovectomy (chemical, radioisotopic, or arthroscopic) to remove inflamed synovium in target joints and reduce recurrent bleeding. Joint arthroplasty (replacement) for end-stage arthropathy.

Recommended Lifestyle Changes

• Avoid contact sports (e.g., football, boxing); encourage low-impact activities like swimming to maintain joint musculature.
• Strictly avoid aspirin, NSAIDs, and IM injections to prevent bleeding.

Patient Counseling & Advice

Educate the patient and family on recognizing early signs of joint bleeding ('aura' or tingling) and self-administering factor therapy immediately. Genetic counseling for family planning.

Follow-Up & Monitoring Schedule

Annual comprehensive care clinic visits (Hematologist, Orthopedist, Physical Therapist). Monitor inhibitor titers annually or if clinical response to factor replacement declines.

Preventive Strategies

Primary prophylaxis (starting factor replacement or Emicizumab before the 2nd joint bleed or by age 3) is the standard of care to prevent joint damage.

With modern prophylaxis, patients have a near-normal life expectancy and can avoid severe arthropathy. However, inhibitor development represents a significant complication that increases morbidity.